ID   SK-BR-3-LR
AC   CVCL_4V52
DR   cancercelllines; CVCL_4V52
DR   Wikidata; Q54953621
RX   PubMed=23811285;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 12
//
RX   PubMed=23811285; DOI=10.1016/j.canlet.2013.06.022;
RA   Wang Q.-R., Quan H.-T., Zhao J., Xie C.-Y., Wang L., Lou L.-G.;
RT   "RON confers lapatinib resistance in HER2-positive breast cancer
RT   cells.";
RL   Cancer Lett. 340:43-50(2013).
//